About Peter Westervelt, MD, PhD
Peter Westervelt, MD, PhD is a medical oncologist with a focus on the treatment of hematologic malignancies, primarily acute leukemias, myelodysplastic syndromes, and stem cell transplantation. Dr. Westervelt was previously on the faculty at Washington University/Siteman Cancer Center in St Louis, where he directed the Leukemia/Stem Cell Transplant Program, and recently relocated back to Maine, where he currently maintains an outpatient clinical practice with MaineHealth Cancer Care in Brunswick. In addition, Dr. Westervelt provides inpatient coverage of the Oncology service at Maine Medical Center in Portland, as well as inpatient coverage of the Leukemia and Stem Cell Transplant services at MGH.
Clinical Interests:
- Acute Leukemia
- Myelodysplastic syndrome (MDS)
- Stem cell transplantation
Treats:
- Adult
Locations
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
- MD, Washington University
- Residency, Barnes Hospital
- Fellowship, Washington University
American Board Certifications
- Oncology, American Board of Internal Medicine
Accepted Insurance Plans
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Harvard Pilgrim Health Care
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Railroad Medicare
- Tufts Health Plan
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
Selected Publications:
- Huselton E, Rettig MP, Campbell K, Cashen AF, DiPersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, Uy GL, Marcus S, Westervelt P. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021 Sep 22;110:106713. doi: 10.1016/j.leukres.2021.106713. Online ahead of print. PMID: 34619434
- Westervelt P. IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation. Lancet Haematol. 2020 Oct;7(10):e698-e699. doi: 10.1016/S2352-3026(20)30287-8. PMID: 32976742
- Westervelt P. Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2020 Mar;26(3):e51-e52. doi: 10.1016/j.bbmt.2019.12.727. Epub 2019 Dec 24. No abstract available. PMID: 31881282
- Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leuk Res. 2016 Oct; 49: 1-6. PMID: 27505705
- Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011 Apr 20; 305(15): 1577-84. PMID: 21505136